Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Tscan Therapeutics stock
Learn how to easily invest in Tscan Therapeutics stock.
Tscan Therapeutics Inc is a biotechnology business based in the US. Tscan Therapeutics shares (TCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Tscan Therapeutics employs 115 staff and has a trailing 12-month revenue of around $12.3 million.
How to buy shares in Tscan Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – TCRX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Tscan Therapeutics stock price (NASDAQ: TCRX)Use our graph to track the performance of TCRX stocks over time.
Tscan Therapeutics shares at a glance
|Latest market close||$2.71|
|52-week range||$1.60 - $9.35|
|50-day moving average||$3.31|
|200-day moving average||$3.58|
|Wall St. target price||$14.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-3.28|
Buy Tscan Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Tscan Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Tscan Therapeutics price performance over time
|1 week (2022-09-21)||-6.55%|
|1 month (2022-08-26)||-9.36%|
|3 months (2022-06-28)||-12.01%|
|6 months (2022-03-28)||-9.97%|
|1 year (2021-09-28)||-68.00%|
|2 years (2020-09-24)||N/A|
|3 years (2019-09-24)||N/A|
|5 years (2017-09-24)||N/A|
Tscan Therapeutics financials
|Revenue TTM||$12.3 million|
|Gross profit TTM||$-34,813,000|
|Return on assets TTM||-27.2%|
|Return on equity TTM||-53.06%|
|Market capitalisation||$65.2 million|
TTM: trailing 12 months
Tscan Therapeutics share dividends
We're not expecting Tscan Therapeutics to pay a dividend over the next 12 months.
Tscan Therapeutics overview
TScan Therapeutics, Inc. , a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. , to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc.
Tscan Therapeutics in the news
TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Frequently asked questionsWhat percentage of Tscan Therapeutics is owned by insiders or institutions?
Currently 12.691% of Tscan Therapeutics shares are held by insiders and 58.528% by institutions. How many people work for Tscan Therapeutics?
Latest data suggests 115 work at Tscan Therapeutics. When does the fiscal year end for Tscan Therapeutics?
Tscan Therapeutics's fiscal year ends in December. Where is Tscan Therapeutics based?
Tscan Therapeutics's address is: 830 Winter Street, Waltham, MA, United States, 02451 What is Tscan Therapeutics's ISIN number?
Tscan Therapeutics's international securities identification number is: US89854M1018
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert